Dyne Therapeutics Inc’s filing revealed that its Officer Kerr Douglas acquired Company’s shares for reported $18231.0 on Dec 05 ’25. In the deal valued at $20.72 per share,880 shares were bought.
Then, Cox John bought 2,662 shares, generating $55,150 in total proceeds.
Before that, Cox John sold 2,662 shares. Dyne Therapeutics Inc shares valued at $55,157 were divested by the CEO & President at a price of $20.72 per share. As a result of the transaction, Cox John now holds 196,877 shares, worth roughly $4.37 million.
Oppenheimer downgraded its Dyne Therapeutics Inc [DYN] rating to a Perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Raymond James’s analysts, who increased its forecast for the stock in late August from “an Outperform” to “a Strong buy”. Bernstein began covering DYN with “Mkt perform” recommendation on June 24, 2025.
Price Performance Review of DYN
On Monday, Dyne Therapeutics Inc [NASDAQ:DYN] saw its stock jump 9.47% to $22.2. Over the last five days, the stock has gained 7.71%. Dyne Therapeutics Inc shares have fallen nearly -24.59% since the year began. Nevertheless, the stocks have fallen -5.77% over the past one year. While a 52-week high of $29.72 was reached on 01/02/25, a 52-week low of $6.36 was recorded on 04/09/25.
Levels Of Support And Resistance For DYN Stock
The 24-hour chart illustrates a support level at 20.90, which if violated will result in even more drops to 19.60. On the upside, there is a resistance level at 23.73. A further resistance level may holdings at 25.26.
How much short interest is there in Dyne Therapeutics Inc?
A steep rise in short interest was recorded in Dyne Therapeutics Inc stocks on 2025-11-14, growing by 14528.0 shares to a total of 17.11 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 17.1 million shares. There was a rise of 0.08%, which implies that there is a positive sentiment for the stock.
